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ABStrAct                         The 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced acute inflammatory bowel 
disease (IBD) model in the rat is discussed, focusing on the details of the TNBS instillation and 
highlighting the advantages and limitations of this model. For determination of the time-
dependent action of 50% ethanol and different doses of TNBS, male Wistar rats were treated 
with 50% ethanol or 10 mg or 30 mg of TNBS dissolved in 50% ethanol. The TNBS-induced 
inflammation peaked 48-72 h after installation and the colitis caused by 30 mg of TNBS was 
more severe than that caused by 10 mg of TNBS. To test the effectiveness of sulfasalazine (SASP), 
male rats were treated with 10 mg of TNBS or with 10 mg of TNBS and SASP, and 72 h later the 
extent of mucosal damage was determined. Orally administered 50 mg/kg/day SASP proved to 
reduce the TNBS-induced colonic inflammation in rats significantly. The TNBS-induced colitis 
model facilitates a better understanding of the immunopathological mechanisms of IBD. Op-
timization of the dose of TNBS and oral SASP as positive control in TNBS-induced colitis in rats 
furnishes an appropriate test system for new anti-IBD drugs.
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Inflammatory bowel disease (IBD) is a chronic disease of 
the gastrointestinal tract, primarily manifested as Crohn’s 
disease (CD) and ulcerative colitis (UC). Environmental, 
genetic and immunological factors all contribute significantly 
to the pathophysiology of IBD, but the precise mechanisms 
remain unclear (Kaser et al. 2010). Epidemiological stud-
ies have revealed an increasing incidence of IBD in north-
western Europe, the USA and eastern Canada, suggesting 
that environmental and lifestyle factors play a major role in 
the development and progression of this disease (Vatn 2008; 
Kappelman et al. 2013; Ng et al. 2013).
Several animal models have been developed in attempts 
to understand the pathogenesis of IBD and to test pharmaco-
logical molecules and therapeutic targets. However, CD and 
UC are chronic diseases, while animal models are necessar-
ily primarily acute, in order to limit the discomfort and the 
pain caused to the animals and to reduce the costs associated 
with the use of reagents and supplies. Invertebrate models 
of IBD, involving Caenorhabditis elegans (Chinnadurai et 
al. 2008; Kang et al. 2010) and Drosophila melanogaster 
(Liu et al. 2010; Apidianakis et al. 2011), have been used 
to investigate the genetic factors and signalling pathways 
involved in the pathogenesis of these diseases and to identify 
novel therapeutic agents (Lin et al. 2011). However, the vari-
ous vertebrate models (most commonly mice and rats) more 
closely resemble the complexity of the human physiology 
than those with invertebrate animals, and may reflect the dif-
ferent subtypes of patients with IBD, and they are important 
in preclinical studies (Jurjus et al. 2004). 
Rodent models of chemically induced IBD are widely 
used because of their simplicity and the possibility of the 
control of the degree of inflammation (Table 1). However, 
the differences in protocols lead to difficulties in reproducing 
reported experiments and in comparing measured parameters 
between studies. The inconsistent variables generally include 
the rodent strains used, the amounts and concentrations of 
chemical agents and the time of sacrifice in relation to the 
treatment. 
The 2,4,6-trinitrobenzenesulfonic acid (TNBS) model 
was originally described by Morris et al. (Morris et al. 
1989). TNBS (0.5 to 4.0 mg for mice and 10 to 30 mg for 
rats) is dissolved in 45% or 50% ethanol, which can lead to 
the destruction of the mucosal barrier. As a hapten, TNBS 
can bind to the endogenous proteins, giving rise to hapten-
protein formation, which induces the interleukin-12 (IL-12) 
and T helper 1-mediated local immunological response. The 
activated macrophages produce inflammatory mediators, 
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such as tumor necrosis factor-α, IL-6 and IL-1α (Ishiguro et al. 
2010; Strober et al. 1998), which in turn result in transmural 
inflammation with weight loss and diarrhoea. The TNBS 
model has many advantages, such as the simple process and 
the short duration of the experiment. Moreover, it is widely 
applicable to vertebrates, including mice (it is important to 
note, however, that the susceptibility to TNBS-induced colitis 
varies between different mouse strains: SJL and BALB/c mice 
are susceptible), rats, guinea pigs and rabbits, and can be used 
either acutely with a single TNBS treatment or chronically 
with the repeated administration of TNBS (Terai et al. 2014). 
On the other hand, this model has the major limitation that it 
cannot mimic the relapsing phase of CD (Table 1).
Among the reference drugs with anti-IBD effects, hy-
drocortisone acetate (20 mg/kg, i.p.), Asacol (100 mg/kg, 
p.o.) (Motavallian-Naeini et al. 2012), 5-aminosalicylic acid 
(5-ASA; 8, 25 or 75 mg/kg, intracolonal) (Horvath et al. 
2008) and the 5-ASA-releasing sulfasalazine (SASP; 360 
mg/kg, p.o.) (Byrav et al. 2013) have been found effective in 
ameliorating inflammation.
The primary aim of the present study was to investigate 
a TNBS-induced acute IBD model in the rat, focusing on 
the details of the TNBS instillation and highlighting the ad-
vantages and limitations of this model, in which anti-colitis 
drugs can be tested. A further aim was to describe a newly 
developed method for treatment with SASP as a positive 
control in a TNBS-induced acute colitis model.
Materials and Methods
Animals 
Male Wistar rats (200-250 g, Toxi-Coop Zrt., Hungary) were 
housed in groups (4 or 5 rats in each cage). Food was with-
drawn overnight before the induction of colitis; otherwise, 
the animals had access to food and drinking water ad libitum 
throughout the experiments. The animal care and research 
protocols were in full accordance with the guidelines of the 
University of Szeged.
experimental design for determination of the 
time-dependent action of 50% ethanol or tNBS 
(10 or 30 mg) dissolved in 50% ethanol 
The animals were randomly divided into three groups, to 
which 50% ethanol (n=36), 10 mg of TNBS (n=27) or 30 mg 
of TNBS (n=90) was administered. 12 h before the induction 
of colitis, the rats were fasted. 
TNBS (also called picrylsulfonic acid, from Sigma-
Aldrich) as received from the manufacturer was aliquoted 
and stored at -20 °C in order to prevent its effectiveness. The 
TNBS solution for administration was prepared immediately 
before treatment: 10 mg or 30 mg of TNBS was dissolved in 
50% ethanol for instillation in a final volume of 250 μl per 
rat. Following dissolution, the TNBS solutions were protected 
from light, because they are light-sensitive and unstable at 
room temperature.
The intracolonic administration of the ethanol or the 
TNBS (dissolved in ethanol) was performed under transient 
ether anaesthesia with the aid of an 8 cm long plastic catheter 
(800/100/260PO, ReplantMed) attached to a 1 ml syringe. 
After the instillation, the rats were kept on their back for about 
30 s before being returned to their cages.
The body weight was measured immediately before and 
24, 48 and 72 h after ethanol or TNBS treatment. 
Both before and 24, 48 and 72 h after treatment with 10 
mg of TNBS, and 1.5, 3, 6, 12, 24, 48 and 72 h and 6 and 10 
days after treatment with 30 mg of TNBS and 6, 12, 24 and 
48 h after treatment with ethanol, rats (n=9 at each timepoint) 
were sacrificed by cervical dislocation under ether anaesthe-
sia, and the 8 cm portion of the colon distal from the rectum 
Table 1. Advantages and disadvantages of the most common chemically-induced animal models of IBD.
Models Advantages Disadvantages References
TNBS Widely applicable to vertebrate animals 
(rats, mice, guinea pigs, rabbits), in which 
the pathology closely resembles the human 
pathology.
Can induce acute or chronic transmural 
inflammation. 
Cannot mimic the relapsing phase of 
Crohn’s disease.
Scheiffele et al. 2002
te Velde et al. 2006 Motaval-
lian-Naeini et al. 2012
Alex et al. 2009
DSS Can induce inflammation in acute, chronic or 
relapsing form.
Longer duration of experiment. Rose et al. 2012
Chen et al. 2007
Perse et al. 2012
Acetic acid The general health of the animals is similar to 
that of the controls.
The treatment is more complex. Yamada et al. 1992
Fabia et al. 1992
Indomethacin Induces inflammation not in the colon, but in 
the ileum and jejunum.
Simple administration (subcutaneous) without 
anaesthesia. 
The inflammation is not localized in the 
colon.
Yamada et al. 1993
Piepoli et al. 2005
TNBS = 2,4,6-trinitrobenzenesulfonic acid, DSS = dextran sulfate sodium
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was dissected, longitudinally opened, gently rinsed with 
ice-cold physiological saline, and photographed (Panasonic 
Lumix DMC-TZ6 digital camera) for determination of the 
extent of macroscopic colonic inflammatory damage.
experimental design for tests of the 
effectiveness of a SASP in the tNBS model 
(Table 2)
The animals were randomly divided into 2 groups, for the 
administration of 10 mg of TNBS (n=9) or 10 mg of TNBS 
+ SASP 50 mg/kg/day (positive control group, n=9). For 12 h 
before the induction of colitis, all of the rats were fasted. The 
animals were treated with TNBS (10 mg dissolved in 50% 
ethanol for a final volume of 250 μl per rat). The detailed steps 
of the TNBS treatment were described above. 
The animals in the positive control group were treated 
with TNBS and SASP as follows: 25 mg/kg SASP was 
dissolved in 1% carboxymethylcellulose (CMC) for a final 
volume of 250 μl per rat. The animals were treated orally 
with SASP solution twice a day for 3 days, the first treatment 
taking place 2 h before the instillation of TNBS.
72 h after the treatment with TNBS, the 8 cm distal seg-
ment of the colon was collected as described above. 
Parameters utilized to analyse the severity of 
the induced inflammation
Body weight change: the weight of each animal was mea-
sured every day, starting on the day before TNBS treatment, 
and the change in weight was calculated as a percentage, the 
baseline (100%) being taken as the weight on the day of the 
TNBS challenge.
Percentage of damaged mucosa: the extent of macroscopi-
cally apparent inflammation, ulceration and tissue disruption 
was determined in a randomized manner from colour im-
ages via computerized planimetry (proprietary computerized 
planimetry software, developed in our laboratory was used: 
Stat_2_1_1). The surface area of macroscopically visible 
mucosal involvement was calculated and expressed as a per-
centage of the surface area of the total 8 cm colonic segment 
under study.
Statistical analysis
Results are shown as means ± S.E.M; statistical comparisons 
were performed with the two-tailed Student t-test.
results
time-dependent changes in colonic 
inflammation induced by 50% ethanol, or by 10 
mg or 30 mg of tNBS
Our findings revealed the role and time-dependent effects 
of ethanol (the vehicle of TNBS) and the different doses of 
TNBS in the development of acute colonic inflammation. 50% 
ethanol give rise to damage to the mucosal barrier 6-12 h after 
treatment, and the macroscopic changes were reversed after 2 
days. The TNBS-induced inflammation peaked 48-72 h after 
instillation, and this was followed by a slow recovery process. 
The maximum extent of the lesion caused by 30 mg of TNBS 
(62.8 ± 5.5% of the 8 cm segment of the colon) was slightly 
greater than that caused by 10 mg of TNBS (58.0 ± 3.0% of 
the 8 cm segment of the colon) (Fig. 1A). Moreover, in the 
30 mg TNBS group 5 rats died during the study, whereas in 
the 10 mg TNBS group there were no deaths. 
Changes in body weight induced by treatment 
with 10 mg or 30 mg of TNBS 
The rats treated with 30 mg of TNBS exhibited a significantly 
greater weight loss as compared with the animals challenged 
with 10 mg of TNBS on the third day (Fig. 1B).
SASP, a positive control for the tNBS colitis 
model
SASP administered orally twice a day in a dose of 25 mg/kg/
day in 1% CMC significantly reduced the colonic inflamma-
Table 2. Treatment groups.
Group (n=9) Treatment Route options Schedule
Absolute control - - -
Vehicle control EtOH Intracolonic Single dose of 250 µl of 50% EtOH
TNBS-treated TNBS in 50% EtOH Intracolonic Single dose of 10 mg/250 µl of 50% EtOH
Positive control
(anti-IBD drug)
TNBS in 50% EtOH
+
SASP in 1% CMC
Intracolonic
Oral
Single dose of 10 mg/250 µl of 50% EtOH
Daily 2 x 25 mg/ 250 µl 1% CMC
Test item
TNBS in 50% EtOH
+
test item
Intracolonic
Oral
Single dose of 10 mg/250 µl of 50% EtOH
Twice daily 
EtOH = ethanol, TNBS = 2,4,6-trinitrobenzenesulfonic acid solution, SASP = sulfasalazine, CMC = carboxymethylcellulose
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tion in the TNBS (10 mg)-treated rats, from 51.2 ± 3.7% to 
28 ± 2.1% 72 h after the TNBS challenge (Fig. 2A). 
The representative images demonstrate that the TNBS (10 
mg) treatment caused macroscopic damage in the 8 cm seg-
ment of the colon, such as ulceration and wall thickening (Fig. 
2B), while the SASP treatment exerted an anti-inflammatory 
effect on the TNBS (10 mg)-induced colitis (Fig. 2C).
discussion
The use of animal models is important for the attainment of a 
better understanding of the pathological mechanisms involved 
in IBD, and such models can contribute to the development 
of new modes of treatments for humans. The present study 
related to a detailed protocol of TNBS treatment in the rat, 
with methods designed to monitor colonic inflammation, 
including the effects of different doses of TNBS, ethanol and 
SASP on the development of colonic inflammation.
TNBS-induced colitis can mimic many of the features 
of CD. The body weight loss is an indicator of the severity 
of the colitis, because TNBS/ethanol treatment causes diar-
rhoea, and the discomfort decreases the appetite (Ibrahim et 
al. 2011). In accordance with previous findings, we found that 
there was a greater decrease in body weight in the rats treated 
with 30 mg of TNBS at 72 h than in those treated with 10 mg 
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Figure 1. Time-dependent changes in the percentage of mucosal damage induced by 10 mg of TNBS, 30 mg of TNBS or 50% ethanol (A). (The 
intermittent x axis shows the time-scale: hours and days.) Results are given as means ± S.E.M., n=7-9. Time-dependent body weight changes 
caused by challenge with 10 mg or 30 mg of TNBS (B). Results are given as means ± S.E.M., *P<0.05 as compared with the 30 mg TNBS group 
on the 3rd day, n=7-9. 
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of TNBS. Moreover, in the 10 mg TBNS group, no rat died 
as a result of the TNBS treatment.
The dose of TNBS and the percentage of ethanol applied 
vary among the reported investigations. In agreement with 
previous studies, we found that the severity of TNBS-induced 
colonic inflammation is dose-dependent (Motavallian-Naeini 
et al. 2012, Brenna et al. 2013). Menozzi et al. observed that 
30 mg of TNBS resulted in the need for a longer regenera-
tion of the histological changes as compared with 10 mg of 
TNBS (Menozzi et al. 2006). The findings relating to the 
body weight changes, the mucosal damage and the survival 
rate following the treatments with the two different doses of 
TNBS suggest that 10 mg of TNBS is a more appropriate dose 
with which to induce colonic inflammation. 
As the time-related changes in ethanol-induced mucosal 
damage indicated, ethanol plays an important role in the 
initial phase (12 h after treatment) of the development of in-
flammation. Hong-Yan Qin et al. demonstrated that the same 
dose of TNBS in different vehicle volumes caused different 
degrees of damage, TNBS in 25% ethanol gave rise to a lower 
pathological score and to a lower level of myeloperoxidase 
activity relative to those after TNBS in 50% ethanol (Qin et 
al. 2012).
We used SASP (brand names Azulfidine in the U.S., and 
Salazopyrin and Sulazine in Europe) as a positive control. 
SASP is a sulfa drug and a widely used anti-colitic agent in 
human IBD therapy. Earlier findings revealed that SASP and 
5-ASA are poorly absorbed in the gut (Yen et al. 2012), while 
5-ASA, the pharmacologically active metabolite of SASP, in-
gested directly into the colon is effective in decreasing colitis 
(Horvath et al. 2008). The oral administration of SASP is 
better than local ingestion of the drug into the inflamed colon, 
as there is then less risk of aggravation of the injury of the 
inflamed colon; moreover, the oral administration of SASP 
can serve as a positive control (Ghatule et al. 2014, Zhang 
et al. 2014). The present study has demonstrated that SASP 
given orally at a dose of 50 mg/kg/day twice a day resulted 
in an improvement in the colonic inflammation induced by 
10 mg of TNBS.
In conclusion, this report has described a chemically-
induced rodent model of intestinal inflammation focusing 
on TNBS-induced acute colitis in rats, a widely-used simple 
animal model characterized by transmural inflammation with 
weight loss. It emerged that 10 mg of TNBS is a more suitable 
dose than 30 mg of TNBS, and, as a reference drug, orally 
administered SASP is preferable to an enema (Horvath et al. 
2008) for attenuation of acute TNBS inflammation in rats. 
This model may promote a better understanding of the 
immunopathological mechanisms of IBD via the testing of 
new compounds in the preclinical phase. It is hoped that this 
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Figure 2. Effect of 50 mg/kg/day sulfasalazine (SASP) on the severity of colonic inflammation induced by 10 mg of TNBS (A). Results are given 
as means ± S.E.M., ***P<0.001 as compared with the TNBS group, n=9. Representative images of the 8 cm colonic segment from each group: 
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detailed description of the TNBS colitis protocol used in our 
laboratory will be helpful to other research teams.
Acknowledgements
This research was realized in the frames of TÁMOP 4.2.4. 
A/2-11-1-2012-0001 “National Excellence Program – Elabo-
rating and operating an inland student and researcher personal 
support system”. The project was subsidized by the European 
Union and co-financed by the European Social Fund.
references
Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola 
M, Li X (2009) Distinct cytokine patterns identified from multiplex 
profiles of purine DSS and TNBS-induced colitis. Inflamm Bowel Dis 
15:341-352.
Apidianakis Y, Rahme LG (2011) Drosophila melanogaster as a model for 
human intestinal infection and pathology. Dis Model Mech 4:21-30.
Brenna Ø, Furnes MW, Drozdov I, van Beelen Granlund A, Flatberg A, 
Sandvik AK, Zwiggelaar RT, Marvik R, Nordrum IS, Kidd M, Gus-
tafsson BI (2013) Relevance of TNBS-colitis in rats: a methodological 
study with endoscopic, historical and transcripttomic characterization 
and correlation to IBD. PLoS One 8(1):e54543.
Byrav DSP, Medhi B, Prakash A, Chakrabarti A, Vaiphei K, Khanduja KL 
(2013) Comparative evaluation of different doses of PPAR-α agonist 
alone and in combination with sulfasalazine in experimentally induced 
inflammatory bowel disease in rats. Pharmacol Rep 65:951-959.
Chen Y, Si JM, Liu WL, Cai JT, Du Q, Wang LJ, Gao M (2007) Induction of 
experimental acute ulcerative colitis in rats by administration of dextran 
sulfate sodium at low concentration followed by intracolonic administra-
tion of 30% ethanol. J Zhejiang Univ Sci B 8:632-637.
Chinnadurai G, Vijayalingam S, Gibson SB (2008) BNIP3 Subfamily BH3-
only proteins: mitochondrial stress sensors in normal and pathological 
functions. Oncogene 27:S114-S127
Fabia R, Willen R, Ar’Rajab A, Andersson R, Ahren B, Bengmark S (1992) 
Acetic acid-induced colitis in the rat: a reproducible experimental model 
for acute ulcerative colitis. Eur Surg Res 24:211-225.
Ghatule RR, Gautam MK, Goel S, Singh A, Joshi VK, Goel RK (2014) 
Protective effects of Aegle marmelos fruit pulp on 2,4,6-trinitrobenzene 
sulfonic acid-induced experimental colitis. Pharmacogn Mag 10:S147-
S152
Horvath K, Varga C, Berko A, Posa A, Laszlo F, Whittle BJ (2008) The 
involvement of heme oxygenase-1 activity in the therapeutic actions of 
5-aminosalicylic acid in rat colitis. Eur J Pharmacol 581:315-323.
Ibrahim A, Mbodji K, Hassan A, Aziz M, Boukhettala N, Coeffier M, Savoye 
G, Dechelotte P, Marion-Letellier R (2011) Anti-inflammatory and 
anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in 
intestinal microvascular endothelium. Clin Nutr 30:678-687.
Ishiguro K, Ando T, Maeda O, Watanabe O, Goto H (2010) Novel mouse 
model of colitis characterized by hapten-protein visualization. Biotech-
niques 49:641-648.
Jurjus AR, Khoury NN, Reimund JM (2004) Animal models of inflammatory 
bowel disease. J Pharmacol Toxicol Methods 50:81-92.
Kang C, Avery L (2010) Death-associated protein kinase (DAPK) and sig-
nal transduction: fine-tuning of autophagy in Caenorhabditis elegans 
homeostasis. FEBS J 277:66-73.
Kappelman MD, Moore KR, Allen JK, Cook SF (2013) Recent trends in the 
prevalence of Crohn’s disease and ulcerative colitis in a commercially 
insured US population. Dig Dis Sci 58:519-525.
Kaser A, Zeissig S, Blumberg RS (2010) Genes and environment: how will 
our concepts on the pathophysiology of IBD develop in the future? Dig 
Dis 28:395-405.
Lin J, Hackam DJ (2011) Worms, flies and four-legged friends: the applicabil-
ity of biological models to the understanding of intestinal inflammatory 
diseases. Dis Model Mech 4:447-456.
Liu W, Singh SR, Hou SX (2010) JAK-STAT is restrained by Notch to 
control cell proliferation of the Drosophila intestinal stem cells. J Cell 
Biochem 109:992-999.
Menozzi A, Pozzoli C, Poli E, Lazzaretti M, Grandi D, Coruzzi G (2006) 
Long-term study of TNBS-induced colitis in rats: focus on mast cells. 
Inflamm Res 55:416-422.
Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL 
(1989) Hapten-induced model of chronic inflammation and ulceration 
in the rat colon. Gastroenterology 96:795-803.
Motavallian-Naeini A, Andalib S, Rabbani M, Mahzouni P, Afsharipour M, 
Minaiyan M (2012) Validation and optimization of experimental colitis 
induction in rats using 2, 4, 6-trinitrobenzene sulfonic acid. Res Pharm 
Sci 7:159-169.
Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Jr., Tysk C, 
O’Morain C, Moum B, Colombel JF, Epidemiology and Natural History 
Task Force of the International Organization of Inflammatory Bowel 
Disease (IOIBD) (2013) Geographical variability and environmental 
risk factors in inflammatory bowel disease. Gut 62:630-649.
Perse M, Cerar A (2012) Dextran sodium sulphate colitis mouse model: traps 
and tricks. J Biomed Biotechnol 2012:718617.
Piepoli AL, De Salvatore G, De Salvia MA, Mitolo CI, Siro-Brigiani G, 
Marzullo A, Grattagliano I, Mitolo-Chieppa D, Palasciano G, Portincasa 
P (2005) Indomethacin-induced ileitis is associated with tensiometric, 
vascular and oxidative changes in the experimental rat model. Eur J 
Clin Invest 35:271-278.
Qin HY, Xiao HT, Wu JC, Berman BM, Sung JJ, Bian ZX (2012) Key 
factors in developing the trinitrobenzene sulfonic acid-induced post-
inflammatory irritable bowel syndrome model in rats. World J Gastro-
enterol 18:2481-2492.
Rose WA, 2nd, Sakamoto K, Leifer CA (2012) Multifunctional role of dex-
tran sulfate sodium for in vivo modeling of intestinal diseases. BMC 
Immunol 13:41.
Scheiffele F, Fuss IJ (2002) Induction of TNBS colitis in mice. Curr Protoc 
Immunol Chapter 15:Unit 15 19.
Strober W, Ludviksson BR, Fuss IJ (1998) The pathogenesis of mucosal 
inflammation in murine models of inflammatory bowel disease and 
Crohn disease. Ann Intern Med 128:848-856.
te Velde AA, Verstege MI, Hommes DW (2006) Critical appraisal of the 
current practice in murine TNBS-induced colitis. Inflamm Bowel Dis 
12:995-999.
Terai T, Osawa S, Tani S, Oishi S, Arai Y, Yamada T, Sugimoto M, Furuta T, 
Kanaoka S, Miyajima H, Sugimoto K (2014) Induction of murine TNBS 
colitis is strictly controlled by a modified method using continuous inha-
lation anesthesia with sevoflurane. Dig Dis Sci 59:1415-1427.
Vatn MH (2008) Recent research in IBD epidemiology. Gastroenterol He-
patol (N Y) 4:413-415.
Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB (1993) 
Mechanisms of acute and chronic intestinal inflammation induced by 
indomethacin. Inflammation 17:641-662.
Yamada Y, Marshall S, Specian RD, Grisham MB (1992) A comparative anal-
ysis of two Models of colitis in rats. Gastroenterology 102:1524-1534.
Yen L, Wu J, Hodgkins PL, Cohen RD, Nichol MB (2012) Medication use 
patterns and predictors of nonpersistence and nonadherence with oral 
5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag 
Care Pharm 18:701-712.
Zhang Y, Zhou R, Zhou F, Cheng H, Xia B (2014) Total glucosides of peony 
attenuates 2,4,6-trinitrobenzene sulfonic acid/ethanol-induced colitis 
in rats through adjustment of Th1/Th2 cytokines polarization. Cell 
Biochem Biophys 68:83-95.
